Coave Therapeutics Receives Grant from the ALS Association to Advance its CTx-TFEB Program as a Potential Treatment for All Forms of ALS
Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies, is delighted to announce that it is one of six organisations sharing $2.9 million in grants from the ALS Association that support the advancement of novel therapies for the treatment of amyotrophic lateral ...
Source: pharmiweb.com